2022
Walker, L. E., FitzGerald, R., Saunders, G., Lyon, R., Fisher, M., Martin, K., . . . Fletcher, T. E. (2022). An Open Label, Adaptive, Phase 1 Trial of High-Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS-CoV-2. CLINICAL PHARMACOLOGY & THERAPEUTICS, 111(3), 585-594. doi:10.1002/cpt.2463DOI: 10.1002/cpt.2463
Sacramento, C. Q., Fintelman-Rodrigues, N., Dias, S. S. G., Temerozo, J. R., Da Silva, A. D. P. D., da Silva, C. S., . . . Souza, T. M. L. (2022). Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells. VIRUSES-BASEL, 14(2). doi:10.3390/v14020374DOI: 10.3390/v14020374
2021
Sae-Heng, T., Rajoli, R. K. R., Siccardi, M., Karbwang, J., & Na-Bangchang, K. (2021). Physiologically based pharmacokinetic modeling for dose optimization of quinine-phenobarbital coadministration in patients with cerebral malaria. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 11(1), 104-115. doi:10.1002/psp4.12737DOI: 10.1002/psp4.12737
Pertinez, H., Rajoli, R. K. R., Khoo, S. H., & Owen, A. (2021). Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5 '-triphosphate exposure to support posology for SARS-CoV-2. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(8), 2121-2128. doi:10.1093/jac/dkab135DOI: 10.1093/jac/dkab135
In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19 (Journal article)
Sacramento, C. Q., Fintelman-Rodrigues, N., Temerozo, J. R., Dias Da Silva, A. D. P., Gomes Dias, S. D. S., da Silva, C. D. S., . . . Souza, T. M. L. (2021). In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 76(7), 1874-1885. doi:10.1093/jac/dkab072DOI: 10.1093/jac/dkab072
Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2? (Journal article)
Stachulski, A. V., Taujanskas, J., Pate, S. L., Rajoli, R. K. R., Aljayyoussi, G., Pennington, S. H., . . . O'Neill, P. M. (2021). Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?. ACS INFECTIOUS DISEASES, 7(6), 1317-1331. doi:10.1021/acsinfecdis.0c00478DOI: 10.1021/acsinfecdis.0c00478
Hobson, J. J., Savage, A. C., Dwyer, A., Unsworth, C., Massam, J., Arshad, U., . . . Rannard, S. (n.d.). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. Nanoscale. doi:10.1039/d1nr00309gDOI: 10.1039/d1nr00309g
Rajoli, R. K. R., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2021). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87(4), 2078-2088. doi:10.1111/bcp.14619DOI: 10.1111/bcp.14619
Hobson, J., Savage, A., Dwyer, A., Unsworth, C., Arshad, U., Pertinez, H., . . . Rannard, S. (2021). Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection. doi:10.26434/chemrxiv.13587035.v1DOI: 10.26434/chemrxiv.13587035.v1
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K. R., Neary, M., . . . Owen, A. (2021). Optimisation and validation of a sensitive bioanalytical method for niclosamide. doi:10.1101/2021.01.13.426426DOI: 10.1101/2021.01.13.426426
Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2. (Journal article)
Pertinez, H., Rajoli, R. K., Khoo, S. H., & Owen, A. (2021). Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.. medRxiv. doi:10.1101/2021.01.03.21249159DOI: 10.1101/2021.01.03.21249159
2020
Cottura, N., Howarth, A., Rajoli, R. K. R., & Siccardi, M. (2020). The Current Landscape of Novel Formulations and the Role of Mathematical Modeling in Their Development. JOURNAL OF CLINICAL PHARMACOLOGY, 60, S77-S97. doi:10.1002/jcph.1715DOI: 10.1002/jcph.1715
Physiologically-based Pharmacokinetic (PBPK) Modeling for Prediction of the Optimal Dose Regimens of Quinine and Phenobarbital Co-administration in Adult Patients with Cerebral Malaria and Seizures (Journal article)
Saeheng, T., Karbwang, J., Rajoli, R. K. R., Siccardi, M., & Na-Bangchang, K. (2020). Physiologically-based Pharmacokinetic (PBPK) Modeling for Prediction of the Optimal Dose Regimens of Quinine and Phenobarbital Co-administration in Adult Patients with Cerebral Malaria and Seizures. doi:10.21203/rs.3.rs-53474/v1DOI: 10.21203/rs.3.rs-53474/v1
Sacramento, C., Fintelman-Rodrigues, N., Temerozo, J., de Paula Dias Da Silva, A., da Silva Gomes Dias, S., dos Santos da Silva, C., . . . Souza, T. M. (2020). The <i>in vitro</i> antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2. doi:10.1101/2020.06.15.153411DOI: 10.1101/2020.06.15.153411
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K., Curley, P., . . . Owen, A. (2020). Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics.. Clinical pharmacology and therapeutics. doi:10.1002/cpt.1909DOI: 10.1002/cpt.1909
Rajoli, R. K. R., Demkovich, Z. R., Flexner, C., Owen, A., & Siccardi, M. (2020). Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using PBPK modelling.. Antimicrobial Agents and Chemotherapy. doi:10.1128/aac.00155-20DOI: 10.1128/aac.00155-20
Rajoli, R. K., Pertinez, H., Arshad, U., Box, H., Tatham, L., Curley, P., . . . Owen, A. (2020). Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis.. medRxiv : the preprint server for health sciences. doi:10.1101/2020.05.01.20087130DOI: 10.1111/bcp.14619
Saeheng, T., Na-Bangchang, K., Siccardi, M., Rajoli, R. K. R., & Karbwang, J. (2020). Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir. CLINICAL PHARMACOLOGY & THERAPEUTICS, 107(5), 1209-1220. doi:10.1002/cpt.1721DOI: 10.1002/cpt.1721
Aljayyoussi, G., Rajoli, R. K. R., Pertinez, H., Pennington, S., Hong, D., O’Neill, P., . . . Biagini, G. (2020). Modelling of Systemic versus Pulmonary Chloroquine Exposure in Man for COVID-19 Dose Selection. doi:10.1101/2020.04.24.20078741DOI: 10.1101/2020.04.24.20078741
Arshad, U., Pertinez, H., Box, H., Tatham, L., Rajoli, R. K. R., Curley, P., . . . Owen, A. (2020). Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics. doi:10.1101/2020.04.16.20068379DOI: 10.1101/2020.04.16.20068379
Bunglawala, F., Rajoli, R. K. R., Mirochnick, M., Owen, A., & Siccardi, M. (2020). Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 75(3), 640-647. doi:10.1093/jac/dkz506DOI: 10.1093/jac/dkz506
Pharmacokinetic Modelling to Study the Biodistribution of Nanoparticles (Chapter)
Rajoli, R. K. R. (2020). Pharmacokinetic Modelling to Study the Biodistribution of Nanoparticles. In Mucosal Delivery of Drugs and Biologics in Nanoparticles (pp. 247-267). Springer International Publishing. doi:10.1007/978-3-030-35910-2_11DOI: 10.1007/978-3-030-35910-2_11
2019
Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies (Journal article)
Atoyebi, S. A., Rajoli, R. K. R., Adejuyigbe, E., Owen, A., Bolaji, O., Siccardi, M., & Olagunju, A. (2019). Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 140. doi:10.1016/j.ejps.2019.105068DOI: 10.1016/j.ejps.2019.105068
Rajoli, R. K. R., Flexner, C., Chiong, J., Owen, A., Donnelly, R. F., Larraneta, E., & Siccardi, M. (2019). Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 144, 101-109. doi:10.1016/j.ejpb.2019.09.011DOI: 10.1016/j.ejpb.2019.09.011
Rajoli, R. K. R., Curley, P., Chiong, J., Back, D., Flexner, C., Owen, A., & Siccardi, M. (2019). Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. JOURNAL OF INFECTIOUS DISEASES, 219(11), 1735-1742. doi:10.1093/infdis/jiy726DOI: 10.1093/infdis/jiy726
2018
Chan, C. Y. S., Roberts, O., Rajoli, R. K. R., Liptrott, N. J., Siccardi, M., Almond, L., & Owen, A. (2018). Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach. DRUG METABOLISM AND PHARMACOKINETICS, 33(4), 179-187. doi:10.1016/j.dmpk.2018.01.004DOI: 10.1016/j.dmpk.2018.01.004
Rajoli, R. K. R., Podany, A. T., Moss, D. M., Swindells, S., Flexner, C., Owen, A., & Siccardi, M. (2018). Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 22(8), 937-944. doi:10.5588/ijtld.17.0515DOI: 10.5588/ijtld.17.0515
Olagunju, A., Rajoli, R. K. R., Atoyebi, S. A., Khoo, S., Owen, A., & Siccardi, M. (2018). Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. AAS Open Research, 1(16). doi:10.12688/aasopenres.12860.1DOI: 10.12688/aasopenres.12860.1
Olagunju, A., Rajoli, R., Atoyebi, S., Khoo, S., Owen, A., & Siccardi, M. (2018). Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. doi:10.12688/aasopenres.12860.1DOI: 10.12688/aasopenres.12860.1
Roberts, O., Rajoli, R. K. R., Back, D. J., Owen, A., Darin, K. M., Fletcher, C. V., . . . Siccardi, M. (2018). Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. Journal of Antimicrobial Chemotherapy, 73(4), 1004-1012. doi:10.1093/jac/dkx515DOI: 10.1093/jac/dkx515
Rajoli, R. K. R., Back, D. J., Rannard, S., Meyers, C. F., Flexner, C., Owen, A., & Siccardi, M. (2018). In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.. Clinical pharmacokinetics, 57(02), 255-266. doi:10.1007/s40262-017-0557-xDOI: 10.1007/s40262-017-0557-x
2017
Rajoli, R. K. R., Flexner, C., Owen, A., Donnelly, R., & Siccardi, M. (2017). Transdermal delivery with microneedle patches using in silico modelling. Belfast.
Moss, D. M., Domanico, P., Watkins, M., Park, S., Randolph, R., Wring, S., . . . Owen, A. (2017). Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(7). doi:10.1128/AAC.00105-17DOI: 10.1128/AAC.00105-17
Marzolini, C., Rajoli, R., Battegay, M., Elzi, L., Back, D., & Siccardi, M. (2017). Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. CLINICAL PHARMACOKINETICS, 56(4), 409-420. doi:10.1007/s40262-016-0447-7DOI: 10.1007/s40262-016-0447-7
Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs (Journal article)
Molto, J., Rajoli, R., Back, D. J., Valle, M., Miranda, C., Owen, A., . . . Siccardi, M. (2017). Use of a physiologically based pharmacokinetic model to simulate drug–drug interactions between antineoplastic and antiretroviral drugs. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 72(3), 805-811. doi:10.1093/jac/dkw485DOI: 10.1093/jac/dkw485
Rajoli, R. K. R. (2017, January 4). Investigation of Long-acting Antiretroviral Nanoformulation Pharmacokinetics Using Experimental and Computational Methods.
Silva, A. H., Lima, E. J., Mansilla, M. V., Zysler, R. D., Mojica Pisciotti, M. L., Locatelli, C., . . . Siccardi, M. (2017). A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo. EUROPEAN JOURNAL OF NANOMEDICINE, 9(2), 79-90. doi:10.1515/ejnm-2017-0001DOI: 10.1515/ejnm-2017-0001
Curley, P., Rajoli, R. K. R., Moss, D. M., Liptrott, N. J., Letendre, S., Owen, A., & Siccardi, M. (2017). Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61(1). doi:10.1128/AAC.01841-16DOI: 10.1128/AAC.01841-16
2016
Rajoli, R. K. R., Podany, A., Swindells, S., Flexner, C., Owen, A., & Siccardi, M. (2016). Simulation of long-acting administration of antituberculosis agents using pharmacokinetic modelling. Liverpool.
Rajoli, R. K. R., Back, D., Rannard, S., Flexner, C., Owen, A., & Siccardi, M. (2016). Long-acting injectable formulations for children and adolescents using PBPK modelling. Swansea.
Rajoli, R. K. R., Back, D., Rannard, S., Owen, A., & Siccardi, M. (2016). Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models. Poster session presented at the meeting of Conference on Retroviral and Opportunistic Infections. Boston, MA, USA.
INVESTIGATION OF DRY POWDER INHALATION AEROSOLISATION PERFORMANCE AT DIFFERENT FLOW RATES FROM A CONVENTIONAL CAPSULE-BASED INHALER DEVICE (Journal article)
Saleem, I. Y., Rajoli, R. K. R., & Diez, F. (2016). INVESTIGATION OF DRY POWDER INHALATION AEROSOLISATION PERFORMANCE AT DIFFERENT FLOW RATES FROM A CONVENTIONAL CAPSULE-BASED INHALER DEVICE. JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 29(3), A4. Retrieved from https://www.webofscience.com/
2015
Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV (Journal article)
Rajoli, R. K. R., Back, D. J., Rannard, S., Meyers, C. L. F., Flexner, C., Owen, A., & Siccardi, M. (2015). Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. CLINICAL PHARMACOKINETICS, 54(6), 639-650. doi:10.1007/s40262-014-0227-1DOI: 10.1007/s40262-014-0227-1
Prediction of Infant Exposure to Maternal Drugs From Breast Milk Using PBPK Modeling (Conference Paper)
Olagunju, A., Rajoli, R., Bolaji, O., Back, D., Khoo, S., Owen, A., & Siccardi, M. (2016, February 21). Prediction of Infant Exposure to Maternal Drugs From Breast Milk Using PBPK Modeling. In CROI.
Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models (Conference Paper)
Rajoli, R. K. R., Siccardi, M., Owen, A., Back, D., & Rannard, S. (2016, February 22). Predicting Utility of Long-Acting Injectables in Paediatric Patients With PBPK Models. In Conference on Retroviral and Opportunistic Infections. Boston, MA. Retrieved from http://www.croiconference.org/
Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies (Journal article)
Moss, D. M., Marzolini, C., Rajoli, R. K. R., & Siccardit, M. (2015). Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 11(8), 1203-1217. doi:10.1517/17425255.2015.1037278DOI: 10.1517/17425255.2015.1037278
2014
Rajoli, R. K. R., Back, D., Rannard, S., Owen, A., & Siccardi, M. (2014). Optimisation of Intramuscular Sustained Release-Nano-Formulations Using In Silico Modelling. Poster session presented at the meeting of Conference On Retroviruses And Opportunistic Infections. Boston, MA, USA.
2013
Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective (Journal article)
Siccardi, M., Rajoli, R. K. R., Curley, P., Olagunju, A., Moss, D., & Owen, A. (2013). Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. FUTURE VIROLOGY, 8(9), 871-890. doi:10.2217/fvl.13.67DOI: 10.2217/fvl.13.67
